Corbus Pharmaceuticals Holdings, Inc.
Income Statement
| Line Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $881.7K | $3.9M | $36.1M | $4.8M | $2.4M | $1.9M | $648.4K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $16.1M | $36.4M | $98.3M | $89.6M | $48.6M | $26.0M | $15.4M | $5.9M |
| SG&A Expense | $18.7M | $20.4M | $28.5M | $23.6M | $13.0M | $9.0M | $6.5M | $3.6M |
| Operating Income | $-39.8M | $-56.0M | $-122.8M | $-77.1M | $-56.7M | $-32.6M | $-20.0M | $-8.9M |
| Operating Margin | — | -6,350.1% | -3,119.2% | -213.3% | -1,176.8% | -1,334.4% | -1,045.6% | -1,365.5% |
| Interest Expense | $3.1M | $2.7M | $1.1M | $0 | — | $3.6K | $3.1K | $2.4K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-42.3M | $-45.6M | $-111.3M | $-71.5M | $-55.7M | $-32.4M | $-20.0M | $-8.9M |
| Net Margin | — | -5,176.4% | -2,826.1% | -197.7% | -1,154.5% | -1,328.6% | -1,046.3% | -1,365.1% |
| EPS (Basic) | $-3.38 | $-3.72 | $-0.47 | $-0.37 | $-0.33 | $-0.22 | $-0.16 | $-0.09 |
| EPS (Diluted) | $-3.38 | $-3.72 | $-0.47 | $-0.37 | $-0.33 | $-0.22 | $-0.16 | $-0.09 |
| Shares Outstanding (Basic) | 12.5M | 12.3M | 234.4M | 194.0M | 171.7M | 166.8M | 134.0M | 112.8M |
| Shares Outstanding (Diluted) | 12.5M | 12.3M | 234.4M | 194.0M | 171.7M | 166.8M | 134.0M | 112.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |